Phase 3 results presented at ASCO show daraxonrasib, an oral RAS-pathway inhibitor, nearly doubled median overall survival to 13.2 months versus 6.7 months with standard chemotherapy in ~500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. The drug reduced the risk of death by roughly 60% but caused treatment-related side effects in about 96% of participants, mainly skin and gastrointestinal issues. Eligible patients may access daraxonrasib via an FDA expanded access program while the manufacturer scales production. Although not a cure and with resistance likely, the findings represent a rare and meaningful advance against a historically “undruggable” cancer.
Daraxonrasib Doubles Median Survival in Phase 3 Trial — A Rare Breakthrough for Metastatic Pancreatic Cancer
Pancreatic cancer has been notoriously difficult to treat effectively, leading to it being one of the deadliest cancers. A drug in Phase 3 called daraxonrasib has shown promising data that suggest a doubling of extension of life compared to standard chemotherapy.getty
New Phase 3 data presented at the American Society of Clinical Oncology (ASCO) meeting show that daraxonrasib, an oral inhibitor of the RAS signaling pathway, produced a meaningful survival benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
Trial Results
The randomized study enrolled about 500 patients whose disease had progressed after prior therapy. Participants received once-daily oral daraxonrasib or standard chemotherapy. Median overall survival was 13.2 months in the daraxonrasib arm versus 6.7 months for patients receiving chemotherapy — roughly a doubling of median survival. Investigators also reported a roughly 60% reduction in the risk of death for patients on daraxonrasib compared with chemotherapy, a result many oncologists view as an important advance in this hard-to-treat disease.
Why This Matters
Pancreatic ductal adenocarcinoma is heavily driven by alterations in the RAS pathway, most commonly KRAS mutations. More than 90% of cases harbor RAS pathway changes. For decades many RAS-driven cancers were considered “undruggable,” so a targeted oral agent that shows a significant survival gain is a major proof of concept.
Safety Profile
Treatment-related adverse events were common: about 96% of patients experienced side effects. The most frequently reported issues were skin reactions (rash, dry skin) and gastrointestinal symptoms (diarrhea, nausea). While most adverse events were manageable, clinicians caution that close monitoring and supportive care are essential.
Patient Access and Supply
Eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma who have exhausted other options may access daraxonrasib through an expanded access program; the sponsor is providing the drug free to qualifying individuals under an FDA mechanism that allows experimental therapies for critically ill patients outside clinical trials. Revolution Medicines, the drug’s developer, has said it expects its manufacturing and distribution capabilities to meet anticipated demand, though scaling up production will be an important operational challenge if the drug is approved.
Context and Cautions
Daraxonrasib is not a cure. Resistance to targeted therapy is likely to develop in many patients, and long-term benefit will need continued study. Still, delivering a sizeable survival improvement in a cancer long considered intractable represents a notable advance. Other recent developments in pancreatic cancer care — including early promising data from an investigational mRNA vaccine and an FDA-approved wearable device that delivers alternating electric fields to disrupt dividing tumor cells — add to a cautiously optimistic landscape.
Patient Perspective: Former U.S. Senator Ben Sasse, who has stage 4 pancreatic cancer, described daraxonrasib as a “miracle drug” that has extended his life and eased his symptoms.
This article was originally published on Forbes.com.
Help us improve.
